Company / Operating Margin
Cue Biopharma, Inc. Operating Margin History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-96.7%
FY2025
5-year range
-4275.1% / -96.7%
FY2021-FY2025
Trend
+78.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin has increased for 3 consecutive years, from -4275.1% in FY2022 to -96.7% in FY2025.
Based on SEC 10-K filings.
-96.7% in FY2025 with a 5-year CAGR of +966.5%.
Improved from -949.9% to -96.7% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- +4178.4pp
- 5-Year Change
- +966.5pp
- 10-Year Change
- -
Key checks
Key Insights
- Cue Biopharma, Inc.'s operating margin has grown for 3 consecutive years.
- In FY2025, operating margin increased 78.4% year-over-year.
- Lowest operating margin in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -96.7% | +78.4% |
| FY2024 | -446.9% | +53.0% |
| FY2023 | -949.9% | +77.8% |
| FY2022 | -4275.1% | -1361.3% |
| FY2021 | -292.6% | +72.5% |
| FY2020 | -1063.2% | +68.6% |
| FY2019 | -3386.7% | -66.6% |
| FY2018 | -2033.4% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026